Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Lorenza Landi, Federica D'IncÃ, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro'Federico Cappuzzo

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p 
Original languageItalian
Pages (from-to)316
Number of pages1
JournalJournal for ImmunoTherapy of Cancer
Volume7
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Landi, L., D'IncÃ, F., Gelibter, A., Chiari, R., Grossi, F., Delmonte, A., ... Cappuzzo, F. (2019). Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer, 7(1), 316. https://doi.org/10.1186/s40425-019-0793-8